LC‐ESI‐MS/MS determination of paclitaxel on dried blood spots

Rao, R. Nageswara; Raju, S. Satyanarayana; Vali, R. Mastan; Sarma, V.U.M.; Sankar, G.

doi:10.1002/bmc.1706

Cited by 15 publications

(5 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The disc represents a volumetric measurement comparable to a liquid measurement. The use of various brands of sampling paper is described in the publications, but the precise nature of the paper is not always mentioned [ 71 ].…”

Section: Review Of Methods Published In the Previous 5 Yearsmentioning

confidence: 99%

Therapeutic Drug Monitoring by Dried Blood Spot: Progress to Date and Future Directions

2014

View full text Add to dashboard Cite

This article discusses dried blood spot (DBS) sampling in therapeutic drug monitoring (TDM). The most important advantages of DBS sampling in TDM are the minimally invasive procedure of a finger prick (home sampling), the small volume (children), and the stability of the analyte. Many assays in DBS have been reported in the literature over the previous 5 years. These assays and their analytical techniques are reviewed here. Factors that may influence the accuracy and reproducibility of DBS methods are also discussed. Important issues are the correlation with plasma/serum concentrations and the influence of hematocrit on spot size and recovery. The different substrate materials are considered. DBS sampling can be a valid alternative to conventional venous sampling. However, patient correlation studies are indispensable to prove this. Promising developments are dried plasma spots using membrane and hematocrit correction using the potassium concentration.

show abstract

Section: Review Of Methods Published In the Previous 5 Yearsmentioning

confidence: 99%

Therapeutic Drug Monitoring by Dried Blood Spot: Progress to Date and Future Directions

2014

View full text Add to dashboard Cite

show abstract

“…Thus, it is necessary to develop and validate an analysis method to investigate the pharmacokinetics and tissue distribution of the novel liposomal formulation of PTX. A number of analytical methods of determining PTX in biological fluids and tissues have been reported, including liquid chromatography–mass spectrometry (LC‐MS), in human, dog, rat, mouse plasma or tissues (Tan et al ., ; Gardner et al ., ; Bulitta et al ., ; Jiang et al ., ; Hou et al ., ; Grobosch et al ., ; NageswaraRao et al ., ; Zhang et al ., ), and high‐performance liquid chromatography (HPLC) in plasma (Suno et al ., ; Mowafy et al ., ). Among these analytical methods, HPLC has been most frequently employed in the pharmacokinetic studies of PTX owing to its simplicity, sensitivity and selectivity.…”

Section: Introductionmentioning

confidence: 97%

Pharmacokinetic and tissue distribution of paclitaxel in rabbits assayed by LC‐UV after intravenous administration of its novel liposomal formulation

Wei

Xue

Yang

et al. 2013

Biomedical Chromatography

View full text Add to dashboard Cite

A simple, rapid and sensitive LC-UV method was developed and validated for the determination of paclitaxel (PTX) in rabbit plasma and tissues. A 2 mL aliquot of acetonitrile and 10 μL ammonium acetate (pH 5.0, 6 m) as extraction agents were used to markedly increase the extraction recoveries and greatly reduce the endogenous substances. The separation was achieved on a C18 column at 30 °C using an acetonitrile-ammonium acetate buffer (pH 5.0, 0.02 m; 55:45, v/v) at a flow rate of 1.0 mL/min; UV detection was used at 227 nm. Good linearity was obtained between 0.025 and 10,000 µg/mL for plasma and between 0.025-200,000 µg/g for tissue samples (r > 0.999). The limit of detection was 6 ng/mL in plasma, 8 ng/g in heart and 12.5 ng/g in other tissues. The limit of quantitation was 25 ng/mL in plasma and heart, 125 ng/g in other tissues. The intra- and inter-day assays of precision and accuracy for all bio-samples ranged from 1.38 to 9.60% and from 83.6 to 114.5%, respectively. The extraction recoveries ranged from 70.1 to 109.5%. Samples were stable during three freeze-thaw cycles or stored in a freezer at -20 °C for 30 days. The assay method was successfully applied to a study of the pharmacokinetics and tissue distribution of novel PTX lung targeting liposomes.

show abstract

“…Despite this, there is a growing interest in the application of DBS in oncology. DBS‐based methods have been described for the measurement of hormone therapy drugs, 42–44 antimetabolites, 45 alkylating agents, 46–49 taxanes, 50–53 vinca alkaloids 54 and topoisomerase inhibitors 55 . However, tyrosine kinase inhibitors are the class for which most DBS‐based studies have been published 56–63 .…”

Section: Sampling Strategiesmentioning

confidence: 99%

Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology

Menz

Stocker

Verougstraete

et al. 2020

Brit J Clinical Pharma

View full text Add to dashboard Cite

There are few fields of medicine in which the individualisation of medicines is more important than in the area of oncology. Under‐dosing can have significant ramifications due to the potential for therapeutic failure and cancer progression; by contrast, over‐dosing may lead to severe treatment‐limiting side effects, such as agranulocytosis and neutropenia. Both circumstances lead to poor patient prognosis and contribute to the high mortality rates still seen in oncology. The concept of dose individualisation tailors dosing for each individual patient to ensure optimal drug exposure and best clinical outcomes. While the value of this strategy is well recognised, it has seen little translation to clinical application. However, it is important to recognise that the clinical setting of oncology is unlike that for which therapeutic drug monitoring (TDM) is currently the cornerstone of therapy (e.g. antimicrobials). Whilst there is much to learn from these established TDM settings, the challenges presented in the treatment of cancer must be considered to ensure the implementation of TDM in clinical practice. Recent advancements in a range of scientific disciplines have the capacity to address the current system limitations and significantly enhance the use of anticancer medicines to improve patient health. This review examines opportunities presented by these innovative scientific methodologies, specifically sampling strategies, bioanalytics and dosing decision support, to enable optimal practice and facilitate the clinical implementation of TDM in oncology.

show abstract

LC‐ESI‐MS/MS determination of paclitaxel on dried blood spots

Cited by 15 publications

References 38 publications

Therapeutic Drug Monitoring by Dried Blood Spot: Progress to Date and Future Directions

Therapeutic Drug Monitoring by Dried Blood Spot: Progress to Date and Future Directions

Pharmacokinetic and tissue distribution of paclitaxel in rabbits assayed by LC‐UV after intravenous administration of its novel liposomal formulation

Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology

Contact Info

Product

Resources

About